Major

This timelin
which repre
version, wh
www.Canc
Overvie
As a result
Today, two
1970s. The
increases.
This progre
chemother
ways of ma
This sectio
progress a
milestones
individual p
Timelin
1846
1880s
r Cance
ne of advances
esents nearly 3
hich includes ti
cerProgress.Ne
ew
t of the nations
o out of three p
e nations canc
ess reflects adv
rapy, surgery, r
anaging nause
on of CancerPro
gainst cancer.
s are the result
patients with ca
e
Adven
In Octo
ether as
This ad
experie
Radic
Baltimo
mastec
remove
Halsted
surroun
cancers
enablin
er Miles
s against cance
30,000 physicia
melines of adv
et.
s investment in
eople live at le
cer death rate h
vances over th
radiation, and
a, pain, and ot
ogress.Net hig
From the first
of rigorously co
ancer.
nt of general
ber 1846, a Bos
s a general ane
vance gains im
nced by surgica
al mastectom
ore surgeon Will
tomy, in which t
ed. This helps re
ds work also lea
nding tissue are
s today. For bre
g many women
stones
er was develop
ans who treat p
vances against
clinical cancer
ast five years a
has dropped 18
e last 40 years
increasingly
her side effects
hlights some o
chemotherapy
onducted clinic
anesthesia
ston dentist nam
sthetic, allowing
mediate and wid
al patients until t
my ushers in
iam Halsted pio
the entire breas
educe recurrenc
ads to similar ap
removed. Thes
ast cancer, how
to avoid maste
ped by the Ame
people with can
a range of com
r research, mor
after a cancer d
8 percent since
s in every area
molecularly ta
s are enabling
of the most imp
(1949) to the n
cal trials, made
opens the do
med William T.G
g surgeons to re
despread attent
that time, and m
n more aggre
oneers a new ap
st and the surrou
ces of the diseas
pproaches for ot
se techniques ar
wever, surgeries
ectomy altogethe
erican Society o
ncer and resea
mmon cancers,
re people are s
diagnosis, up f
e the early 1990
of cancer care
argeted treatm
patients to live
ortant advance
newest targete
e possible by th
oor for mode
G. Morton provid
emove a tumor
tion, ultimately e
making the mod
essive surgic
pproach to remo
unding lymph no
se, which was p
ther cancers, in
re still an impor
s have become
er.
of Clinical Onc
arch new cures
, is available on
surviving cance
from roughly on
0s, reversing d
e: prevention, s
ents. At the sa
e better, more f
es that have co
ed treatments, n
he participation
ern cancer s
des the first pub
from a patients
eliminating the e
ern era of surge
cal approach
oving breast tum
odes and chest
previously nearl
n which both the
rtant part of trea
far more conse
cology (ASCO),
. An interactive
nline at
er than ever be
ne out of two in
decades of
screening,
ame time, bette
fulfilling lives.
ontributed to
nearly all of the
n of thousands
urgery
blic demonstratio
s jaw without pa
excruciating pai
ery possible.
hes for cance
mors, radical
muscles are
y always fatal.
e tumor and
atment for some
rvative and effe
1
,
e
efore.
n the
er
ese
of
on of
in.
in
er

ective,




1903
1937
1943
1947
1949


First u
Five ye
radioac
radiatio
other tu
pieces o
at close
to more
Nation
Preside
researc
Introd
The Pa
cancers
Pap tes
remains
treatme
First-e
Sidney
leukem
landma
diagnos
of patie
First c
Followin
and Dru
as mus
through
drug sti
use of radiati
ars after Marie
ctive element to
n becomes wid
umors. In these
of radioactive m
e range. Brachyt
e precisely targe
nal Cancer In
ent Franklin D. R
ch on the causes
duction of Pa
p test, named fo
s or pre-cancers
st has helped to
s a major cause
ent is limited.
ever remissio
Farber, a physi
ia in a 4-year-ol
rk scientific pap
sed. While early
nts in the decad
chemotherap
ng results of clin
ug Administratio
tard gas and sto
h a process calle
ll receives some

ion to treat c
Curies discove
treat cancer, in
ely used to trea
first decades, d
material are impl
therapy remains
et tumor cells wh
nstitute estab
Roosevelt signs
s, diagnosis and
ap test leads
or its inventor, G
s before they ha
reduce U.S. ce
e of cancer deat
on of pediatr
cian at Children
ld girl using the
per. Until this tim
y remissions pro
des to come, all
py drug appr
nical trials cond
on (FDA) for the
ockpiled as a we
ed alkylation. Its
e use today in c

cancer
ry of radium, do
two Russian pa
at many different
octors use an a
anted inside or
s an essential p
hile leaving hea
blished
legislation esta
d treatment of c
to dramatic
George Papanic
ave a chance to
ervical cancer de
th in developing
ric leukemia
ns Hospital Bos
drug aminopter
me, children with
ove temporary, t
owing most chi
roved for can
ucted in 1946 a
e treatment of Ho
eapon in World
s discovery spur
combination che
octors report the
atients with skin
t cancers, includ
approach known
next to tumors,
part of cancer tre
althy tissue unha
ablishing the Na
cancer. The new
declines in c
colaou, enables
spread. Since t
eath rates by ne
countries, whe
ston, achieves th
rin. He soon doc
h acute leukemi
they pave the w
ldhood cancer p
ncer
and 1947, nitrog
odgkin lymphom
War II kills ca
rs rapid advanc
emotherapy for
Major Can
e first successfu
n cancer. In the
ding cervical, pr
n as brachythera
, delivering radia
eatment today,
armed.
ational Cancer In
w agencys 1938
cervical canc
doctors to dete
the 1950s, wide
early 70 percent
ere access to sc
he first partial re
cuments 10 cas
ia usually died w
way for therapies
patients to live l
gen mustard is a
ma. Nitrogen mu
ancer cells by m
cements in chem
Hodgkin lympho
ncer Milest
ul of use of this
following decad
rostate, breast a
apy, in which sm
ation to cancer
but has been re
nstitute to suppo
8 budget is $400
cer deaths
ect and treat cer
espread use of t
t. Yet cervical c
creening and
emission of ped
ses of remission
within weeks of
s that cure thou
ong, healthy liv
approved by the
ustard also kn
modifying their D
motherapy, and
oma.
ones
2
des,
and
mall
cells
efined
ort
0,000.
rvical
the
cancer
diatric
n in a
being
sands
es.
e Food
nown
DNA
the




1955
1958
1950s
1960s
1960
1965
U.S. g
treatm
The Clin
time, th
importa
brought
lumpec
others.
percent
increas
Pione
NCI sci
togethe
stage fo
carefull
Smok
In the 1
the earl
linking s
as a ma
smoker
reducin
Resea
Investig
later, re
9 and 2
first-eve
myelog
Chem
Resear
(mechlo
advanc
differen
ABVD)
lympho
government e
ments
nical Trials Coo
is nationwide ca
ant advances in
t breakthroughs
tomy to avoid m
Perhaps most s
t of children with
ed from less tha
ering comb
entists demonst
er can cause r
or nearly all mod
y refined to max
ing linked to
950s, studies b
ly 1960s, both th
smoking to canc
ajor cause of pa
rs. Tobacco con
g the worldwide
archers link
gators in Philade
esearchers disco
22 switch place
er targeted canc
enous leukemia
otherapy fou
chers led by Vin
orethamine, vinc
ed Hodgkin lym
nt chemotherapy
proves even mo
ma. The ABVD

establishes n
operative Group
ancer research
cancer treatme
s in adjuvant che
mastectomy; and
striking is the im
h cancer are en
an 10 percent in
bination chem
trate that combi
emissions in bo
dern chemother
ximize effective
o cancer; ces
begin to show th
he U.S. Surgeo
cer and other se
ancreatic cancer
ntrol and smokin
e toll of lung can
Philadelphia
elphia identify a
over that this ab
es in a phenom
cer treatments,
a and other canc
und to cure H
ncent DeVita dis
cristine, procarb
mphoma. This re
y combination (d
ore effective, cu
combination re

national rese
Program is esta
network proves
nt, screening an
emotherapy for
d new standards
mpact of these tr
rolled in clinical
n the 1950s to n
motherapy c
ination chemoth
oth children and
rapy, in which d
ness while mini
ssation camp
at smoking is a
n General and t
erious health pro
r, and second-h
ng cessation soo
ncer.
a chromosom
chromosomal a
bnormality resul
enon called tran
imatinib (Gleeve
cers.
Hodgkin lym
scover that a ne
bazine and pred
egimen quickly b
doxorubicin, ble
uring about 70 p
mains a mainst
earch networ
ablished by the
s the safety and
nd prevention. C
breast and colo
s of care for blo
rials on pediatric
trials, and child
nearly 80 percen
cures leukem
herapy in whic
adults with acu
rug combination
mizing side effe
paigns begin
a major cause of
the U.K. Royal C
roblems. In later
hand smoke is d
on become the
me to leuke
abnormality link
ts when parts o
nslocation. It lat
ec), which trans
phoma
ew chemotherap
dnisone) cures u
becomes the sta
eomycin, vinblas
percent of patien
tay of treatment
Major Can
rk to test new
U.S. National C
efficacy of man
Cooperative Gro
on cancers; brea
ood cancers, bra
c cancer surviva
dhood cancer su
nt today as a re
mia
ch multiple drug
ute leukemia. Th
ns, dosing and s
ects.
n
f cancer, particu
College of Phys
r years, smoking
declared a threa
most important
emia
ked to many leu
of two chromoso
ter becomes the
sforms treatmen
py regimen calle
up to 50 percent
andard treatmen
stine and dacarb
nts with advanc
t today.
ncer Milest
w cancer
Cancer Institute
ny of the most
oup trials have
ast-conserving
ain tumors, and
al rates. Fifty to
urvival rates hav
sult.
gs are administe
heir findings set
scheduling have
ularly lung canc
sicians issue rep
g is also establi
at to the health o
strategies for
kemias. A deca
omes chromos
e target of one o
nt of chronic
ed MOPP
t of patients with
nt. In the 1970s
bazine known
ced Hodgkin
ones
3
. Over
many
60
ve
ered
t the
e been
er. In
ports
shed
of non-
ade
somes
of the
h
, a
n as




Early 1970
Late 1960s
early 1970
1971
1971
1970s
0s Increa
Studies
compar
sources
directly
Brachyt
adoptio
approac
s
0s
Scree
In 1967
one of t
in stool
few yea
to exam
these a
usually
in color
Nation
Preside
a nation
cancer
years. A
Institute
researc
More l
While ra
called to
muscle
cancer.
the way
CT sc
treatm
Resear
suspect
doctors
decade
tumors,
ased use of r
s suggest that an
red to surgical re
s or seeds are
to the tumor wh
therapy has bee
n of external be
ch once again b
ning tests fo
7, the guaiac fec
the most commo
, a sign that can
ars, two new scr
mine the colon u
pproaches lead
curable with su
ectal cancer mo
nal Cancer A
ent Richard M. N
nal War on Can
research efforts
Among other ch
e ($400 million i
ch facilities and
limited mast
adical surgery h
otal mastectomy
and underarm
The procedure
y for future brea
anning prov
ments
chers perform t
ted brain tumor.
for the first time
s, CT scanning
and to carefully

radioactive
n approach call
emoval of the p
implanted direc
hile leaving hea
en used since th
eam radiation. W
becomes a cent
or colorectal
cal occult blood
on forms of can
ncerous or preca
reening techniqu
using a small ca
ds to better dete
rgery. Over the
ortality a total
Act of 1971 be
Nixon signs the
ncer in his State
s in the U.S., pa
hanges, the Act
n 1972 and $60
award new rese
tectomy prov
had been routine
y (removing jus
lymph nodes) is
e reduces pain a
st-conserving s
ides clearer
he first compute
. CT scanning u
e to clearly see
enables doctor
y target radiatio

seeds to ta
ed brachytherap
rostate and sur
ctly into the pros
lthy tissue beyo
he early 1900s,
With refined tech
ral part of treatm
cancer dram
test (FOBT) is i
cer. This simple
ancerous growt
ues flexible si
mera attached t
ection of precanc
coming decade
decline of more
ecomes law
National Cance
e of the Union a
aving the way fo
provides unprec
00 million by 197
earch grants.
ven effective
ely used to treat
t the breast tiss
s confirmed to b
after surgery and
urgeries.
images of tu
ed tomography
uses X-rays to c
tumors arising
rs to assess the
on and surgery t
arget prostate
py extends the
rrounding tissue
state gland, del
ond the prostate
but became les
hniques and con
ment for prostat
matically redu
introduced as a
e and inexpensi
ths (called polyp
gmoidoscopy a
to a flexible ligh
cerous polyps a
es, routine scree
e than 40 percen
er Act in Decem
address. The ac
or much of the p
cedented levels
74) and directs
e for early-sta
t breast cancer,
sue instead of re
be as effective fo
d speeds recov
umors, guidi
(CT) scan on a
create images o
in the soft tissu
e size, shape an
to hit the tumors
Major Can
e and other c
lives of patients
e. In this approa
ivering a high d
e relatively unaff
ss common afte
nclusive data on
te, cervical and
uce deaths
screening test
ive tool detects
ps) may be pres
and colonoscopy
hted tube. The w
and early stage
ening contribute
nt since 1975.
ber, less than a
ct leads to a ma
progress achieve
s of funding for t
NCI to expand
age breast ca
, a more limited
emoving the bre
or women with e
very for patients.
ng radiation
human patient
r slices of the
e of the brain. O
nd location of ma
s without harmin
ncer Milest
cancers
s with prostate c
ch, tiny radioact
dose of radiation
fected.
er the widesprea
n its effectivene
other cancers.
for colorectal ca
the presence o
sent. Within the
y enable phys
widespread use
cancers that ar
es to major redu
a year after laun
ajor expansion o
ed over the nex
the National Ca
federal cancer
ancer
surgical proced
east, chest wall
early-stage brea
. This advance
and other
a woman with
brain, allowing
Over the followin
any other types
ng healthy tissu
ones
4
cancer,
tive
n
ad
ss, the
ancer,
f blood
next
sicians
of
e
uctions
nching
of
xt 40
ncer
dure
ast
paves
h a
ng
of
e.




1970s
19751976
1977
1977
Late 1970s
Use of
As stud
to decli
health r
exposu
cancer
occur d
ahead.
6 First a
After ov
Bernard
adjuvan
involve
methotr
disease
stage b
This fin
and lun
New tr
A pivota
(Blenox
FDA the
percent
from the
advanc
Many
Studies
entire b
breast c
cancer
lives.
s Growi
Regula
cancers
40 are s
resultin
U.S. wo
f cancer-cau
dies confirm long
ne. In the 1980s
regulations help
re has been sho
in the chest or a
ecades after ex
adjuvant che
vercoming conc
d Fisher and Gia
nt chemotherapy
use of the drug
rexate and fluor
e, improving sur
reast cancer ar
ding sets the st
g cancer, makin
reatments cu
al trial shows th
xane) can cure 7
e following year
t. In recent year
e disease and
es, and to the v
women with
s show that a pro
breast followed
cancer. The find
treatment and e
ing use of ma
r breast cancer
s at an earlier, m
screened. By 20
g early detectio
omen since 197

using asbesto
g-suspected link
s, its use is ban
p to dramatically
own to increase
abdomen), and
xposure, howeve
emotherapy i
erns in the canc
anni Bonadonna
y prolongs the
gs l-phenylalanin
rouracil. Adjuvan
rvival and cure r
e alive five year
age for researc
ng it one of the
ure men with
at combining th
70 percent of pa
r. Today, the ove
rs, the cyclist La
d his subsequen
vital role of clinic
h breast canc
ocedure called
d by radiation th
ding helps dram
enables women
ammography
screening with
more treatable s
008, the proport
n have contrib
5.

os declines
ks between asb
ned in a growin
y limit exposure
e a persons risk
other serious h
er, the impact o
ncreases cu
cer community a
a demonstrate t
e lives of women
ne mustard or a
nt chemotherap
rates in the year
rs after their dia
h on adjuvant th
most important
h testicular c
e drugs cisplati
atients with adva
erall cure rate fo
ance Armstrong
nt Tour de Franc
cal trials in prog
cer can opt fo
lumpectomy i
herapy is as effe
atically reduce
to recover mor
y saves lives
mammography
stage. By the mi
tion screened a
buted to a 27 pe
bestos and certa
ng number of ap
to asbestos in w
k of lung cancer
ealth problems.
of preventive effo
ure rates for e
about whether t
that chemothera
n with early stag
combination of
py becomes a m
rs ahead. Today
agnosis.
herapy in other
advances in mo
cancer
n, vinblastine (V
anced testicular
or testicular can
s high-profile d
ce victories ha
ress against ca
or breast-co
nvolving the rem
ective as mastec
the physical an
re quickly after s
s
y becomes incre
id-1980s, nearly
pproaches 70 p
ercent reduction
Major Can
ain cancers, use
pplications, and
workplaces and
r, mesothelioma
. Because these
forts will be felt g
early-stage b
the benefits outw
apy after surger
ge breast cance
f cyclophospham
major componen
y, about 9 in ten
common cance
odern cancer ca
Velban, Velsar)
r cancer. Cispla
ncer (all stages)
iagnosis, treatm
ave brought new
ncer.
nserving sur
moval of only th
ctomy for wome
d cosmetic side
surgery and retu
easingly commo
y one-third of U
percent. High sc
n in breast canc
ncer Milest
e of asbestos be
environmental a
d homes. Asbest
a (an aggressive
e problems ofte
gradually in the
breast cance
weigh the risks,
ry known as
er. Their studies
mide (Cytoxan),
nt of treatment fo
n women with e
ers, including co
are.
and bleomycin
atin is approved
) is a remarkabl
ment and recove
w attention to th
rgery
he tumor, and no
en with early-sta
e effects of brea
urn to their norm
on, helping to de
.S. women over
creening rates
cer mortality amo
ones
5
egins
and
tos
e
n
years
er
Drs.
s
,
or the
arly-
olon
by the
e 95
ery
hese
ot the
age
ast
mal
etect
r age
and
ong




1981
1982
1986
1986
1986
1986
First c
The FD
1991, th
acute h
vaccina
vaccina
Limite
A new p
many p
rectum,
cancer
connec
PSA te
The FD
commo
PSA tes
whethe
slow-gr
Secon
The U.S
that sec
years th
Tamox
Tamoxi
cancer
reduces
Globa
Pain is
the Wor
focusing
about a
Adhere
In later
talk to t
cancer vacci
DA approves the
he U.S. begins r
epatitis B cases
ation is expected
ated as children
ed surgery he
procedure called
atients with rect
allowing patien
had to undergo
ted to a colosto
est enables e
DA approves the
n form of cance
sting leads to a
r such screenin
owing cancers t
nd-hand smo
S. Surgeon Gen
cond-hand smok
hat follow.
xifen reduce
fen (Novaldex)
surgery, based
s the risk of can
al guidelines
common among
rld Health Orga
g on stronger, o
addiction, toleran
nce to the guide
years, other org
heir patients ab

ne prevents
e first vaccine ag
routine vaccinat
s among childre
d to reduce rate
.
elps rectal c
d total mesorec
tal cancer. The
nts to maintain n
permanent colo
my bag).
early detecti
e first PSA (pros
er in men in m
significant jump
g improves surv
that would neve
oke formally
neral, and later t
ke is a carcinog
es breast can
is approved as
on studies show
ncer recurrence
help ensure
g patients with a
nization issues
opioid-type drug
nce and abuse,
elines has been
ganizations, inc
bout pain and its

cancer-caus
gainst hepatitis
tion of all childre
en under 15 yea
es of liver cance
ancer patien
ctal excision eme
procedure invo
normal bowel fu
ostomies (elimin
on of prosta
state-specific an
en aged 50 and
p in early-stage
vival or simply le
er have become
declared a c
the Internationa
gen. A number o
ncer recurren
adjuvant therap
wing that use of
and dramaticall
proper pain
advanced cance
clear guidance
s such as morp
which made so
n found to provid
luding ASCO, p
s management.
sing hepatitis
B, one of the pr
en against hepa
ars declines by 9
er in the U.S. an
nts avoid colo
erges as a new
olves removing o
unction. Previou
nation of waste
ate cancer
ntigen) test to sc
d older. In the ye
prostate cance
eads to diagnos
e life-threatening
carcinogen
al Agency for Re
of cities around
nce
py for post-men
f the hormonal t
ly increases sur
n managemen
er but hasnt alw
on the use of p
phine. The guide
ome providers re
de reliable pain
propose guidelin
Major Can
s B infection
rimary causes o
atitis B, and by 2
98 percent. Ove
d globally amon
ostomies
w standard surgic
only the cancero
sly, nearly all pa
through an ope
creen for prostat
ears that follow
r diagnoses, sp
sis and unneces
g.
esearch on Can
the world ban in
opausal women
therapy for five
rvival.
nt
ways been well-
pain medications
elines address w
eluctant to pres
relief for up to 9
nes to help doct
ncer Milest
n
of liver cancer. In
2007, the numb
er time, routine
ng adults who w
cal treatment fo
ous region of th
atients with rect
ening in the abd
te cancer the
, widespread us
parking debate a
ssary treatment
cer, officially sta
ndoor smoking
n following brea
years after surg
-managed. In 19
s for cancer pat
widespread con
cribe the drugs
90 percent of pa
tors recognize a
ones
6
n
ber of
were
or
e
tal
omen
most
se of
about
of
ate
in the
st
gery
986,
ients,
ncerns
.
atients.
and




19851991
Late 1980s
1989
Early 1990
Early 1990
Early 1990
1 Adjuv
Pivotal
III color
newer d
further.
a 40 pe
s Benze
Scientis
related
lympho
themse
Drugs
The FD
patients
drugs a
(Neulas
safer by
0s Lapar
Beginni
uses te
some c
recover
0s Shift t
Thanks
radiatio
vastly m
radiatio
minimiz
0s Cance
For the
Nationa
Society
1991 an
vant therapy
clinical trials sh
rectal cancer red
drugs, radiation
Together with g
ercent reduction
ene discover
sts find that occ
products, is ass
ma, and other d
lves from benze
s to boost blo
DA approves the
s with severe an
are soon joined b
sta). The new tre
y reducing the r
oscopic surg
ing in the 1990s
lescoping equip
ancers, includin
r faster and exp
to 3-D radiati
to the integratio
n therapy by cre
more computing
n can be target
ze the damage t
er deaths beg
first time since
al Cancer Institu
y report that the
nd 2008 (the mo

proven for c
ow that chemot
duces the risk o
and sophisticat
greater screenin
in colon cancer
red to cause
upational expos
sociated with inc
diseases. Follow
ene exposure a
ood cells hel
e drug epoetin a
nemia, one of th
by white blood c
eatments help r
isk of infections
gery minimiz
s, laparoscopic s
pment to remove
ng kidney, prosta
erience less pa
ion treatmen
on of powerful c
eating 3-D treat
power than ear
ed at tumors fro
to healthy, surro
gin steady de
record-keeping
ute, the Centers
overall cancer d
ost recent year a

olorectal can
therapy followin
of cancer recurre
ted treatment sc
ng to detect colo
r mortality in the
blood cance
sure to benzene
creased risk of d
wing this discove
nd reduce their
lp patients fi
lpha (Procrit, Ep
he most commo
cell-boosting dru
reduce the need
s and related ho
zes pain, rec
surgery in wh
e tumors eme
ate and colorec
in, without sacri
nt plans incre
computers into m
tment plans. The
rlier, two-dimen
om multiple ang
ounding tissue.
ecline
g began in the 19
for Disease Co
death rate fell b
available), the d
ncer
g surgery (adju
ence by about 4
chedules help
on cancer early
e U.S. since the
ers
e, a chemical co
developing non
ery, workers be
cancer risk.
nish cancer
pogen) to stimu
n and serious s
ugs such as filg
d for blood trans
ospitalizations.
covery time fo
ich a surgeon m
erges as an alte
ctal cancer. This
ificing effectiven
eases precis
medicine, docto
ese plans requi
sional treatmen
les, with beams
930s, cancer m
ontrol and Preve
by 2.6 percent be
death rate has f
Major Can
vant treatment)
40 percent. Late
p to lower recurr
, adjuvant thera
e 1970s.
ommonly used a
n-lymphocytic le
egin taking steps
treatment, re
ulate production
side effects of ch
grastim (Neupog
sfusions and ma
for several ca
makes several s
rnative to traditi
s new approach
ness.
sion, safety o
ors are able to d
re highly compl
nt plans. Thanks
s of varying pow
mortality rates be
ention, and the A
etween 1991 an
fallen by a total
ncer Milest
in patients with
er refinements
rence rates even
apy has contribu
as a solvent and
ukemia, non-Ho
s to protect
educe infect
of red blood ce
hemotherapy. T
gen) and pegfilg
ake chemothera
ancers
small incisions a
ional open surg
allows patients
of therapy
dramatically imp
lex calculations
s to this advanc
wer, in ways that
egin to decline. T
American Canc
nd 1995. Betwe
of 18 percent.
ones
7
h stage
using
n
uted to
d in oil-
odgkin
tions
ells in
These
grastim
apy
and
ery for
s to
prove
and
e,
t
The
er
en




1991
1992
1970s
1990s
19921994


Power
Ondans
radiatio
drugs a
These a
receive
Sentin
A surgic
cancer
procedu
and e
further l
number
as lymp
Sentine
Melan
A growi
increas
of the b
researc
medica
and oth
4 Taxan
A new f
cancer.
ovarian
Later st
ovarian
Over th
and del
adjuvan
field of
synthet
needed
rful anti-naus
setron (Zofran) i
n. The drug wo
are soon approv
and other anti-n
chemotherapy
nel lymph no
cal technique ca
has spread in p
ure involves sur
examining it und
lymph nodes ar
r of nodes. This
phedema, a pain
el lymph node bi
noma linked t
ing number of s
es the risk of m
body without sun
chers continue to
l associations h
her skin cancers
nes emerge a
family of treatme
The drug recei
tumors by more
tudies show it ex
cancer, along w
e next decade,
aying disease p
nt therapy (after
research explor
ic method for pr
d to produce the

sea drugs al
is approved by t
rks by deactivat
ved, including gr
nausea drugs, lik
in an outpatient
ode biopsy de
alled sentinel lym
patients with ear
rgically removin
der a microscope
re removed and
allows for easie
nful swelling of t
iopsy is later fou
to sun expos
tudies indicate t
elanoma. Howe
n exposure, suc
o seek a better
have cautioned a
s.
as a vital che
ents debuts with
ves one of the f
e than half in m
xtends survival
with the chemot
paclitaxel also
progression com
r surgery). The d
ring natural cur
roducing the dru
drug would not

leviate majo
the FDA to prev
ting the nervous
ranisetron (Kytri
ke aprepitant (E
t setting, with m
etermines ca
mph node biops
rly-stage melano
g the lymph nod
e for evidence o
the patient is s
er recovery and
the extremities.
und to be effect
sure
that excessive s
ever, researcher
ch as on the palm
understanding o
against excessiv
emotherapy o
h the FDA appro
fastest-ever app
any women wh
by over a year
therapy drug cis
proves effective
mpared to existin
drug is derived f
res for a range o
ug, there was w
t meet demand.
or side effect
vent vomiting ca
s systems natu
il), dolasetron (A
Emend), make it
minimal disruptio
ancers spre
sy becomes a le
oma, the most a
de closest to the
of cancer. If the
pared the previo
d reduces the ris
tive for women w
sun exposure, i
rs caution that s
ms of the hands
of melanomas
ve sun exposur
option for ov
oval of paclitaxe
provals, on the h
o had stopped
when used as a
splatin.
e for all stages o
ng therapies, an
from the bark of
of diseases. Un
widespread conc
.
Major Can
of cancer tr
aused by chemo
ral trigger for vo
Anzemet) and p
t possible for mo
on to their daily
ad with fewe
ess invasive wa
aggressive form
e primary tumor
sentinel node i
ous practice of
sk of postoperat
with breast canc
ncluding a histo
some melanoma
s and soles of th
risk factors, a n
re to reduce the
varian, breas
el (Taxol) for ad
heels of data sh
responding to a
an initial therapy
of breast cancer
nd delaying recu
f a yew tree, an
ntil drugmakers d
cern that the nat
ncer Milest
reatment
otherapy and/or
omiting. Other, s
palonosetron (Al
ost cancer patie
routines.
er side effect
ay to assess whe
m of skin cancer
r the sentinel
s cancer-free, n
removing a larg
tive side effects
cer.
ory of severe su
as can occur in
he feet. While
number of leadin
risk of melanom
st cancer
dvanced ovarian
howing it shrinks
all other therapie
y for advanced
r extending liv
urrence when u
nd is the product
discovered a
tural resources
ones
8
r
similar
loxi).
ents to
ts
ether
. The
node
no
ge
such
nburn,
areas
ng
ma
n
s
es.
ves
sed as
t of a




1997
1997
Late 1990s
Late 1990s



FDA a
The FD
cell non
drugs c
cells, in
cure rat
Surge
In gene
spread
has me
underw
of all of
emissio
unnotic
s Proph
risk
In the m
and BR
studies
to reduc
(mastec
confirm
reduces
percent
s New r
tissue
Doctors
to preci
from rad
and inte
cancers
glands,
approves firs
DA approves the
n-Hodgkin lymph
called monoclon
nterfering with th
tes and increase
ery found to c
eral, metastatic c
throughout the
tastasized to th
went surgery betw
f these patients
on tomography,
ed before, helpi
hylactic surge
mid-1990s, rese
RCA2 have a sig
find that wome
ce their cancer
ctomy), ovaries
s that removal o
s the risk of brea
t.
adiotherapy
e
s begin using int
sely target tumo
diation. IMRT u
ensity of radiatio
s; IMRT allows d
reducing side e

st-ever target
e first molecularl
homa that no lo
al antibodies, a
he development
e survival.
cure some p
cancer is difficu
body. But in 19
e liver only can
ween 1960 and
were found to h
or PET scannin
ing surgeons in
ery helps pre
archers discove
gnificantly increa
n with the muta
risk by 90 perce
(oophorectomy
of the ovaries a
ast cancer by 5
technique e
tensity modulate
ors that lie close
ses sophisticate
on. One of the c
doctors to minim
effects without c

ted cancer d
y targeted canc
nger responds t
nd targets a pro
t of cancer. It is
atients with
lt or impossible
97, researchers
be cured with s
1987, about on
have been esse
ng, can identify s
the study to ac
event breast
er that women w
ased risk of dev
tions, or with a
ent or more by u
y), or both. A dec
nd fallopian tub
1 percent and th
nables preci
ed radiation the
e to vital organs
ed software and
clearest benefits
mize radiation ex
compromising tu
rug, rituxima
cer drug, rituxim
to other treatme
otein on the surf
later combined
advanced co
to treat with su
s find that some
surgery. In a stu
ne in four were s
ntially cured. A
some liver meta
chieve a cure rat
t and ovarian
who have mutat
veloping breast a
strong family hi
undergoing surg
cade later, a ma
bes in premenop
he risk of ovaria
ise targeting
erapy (IMRT), a
s and other sens
d complex new m
s has been in th
xposure to the s
umor control.
Major Can
ab
mab (Rituxan), to
ents. Rituximab
face of immune
with other canc
olon cancer
urgery because t
e colon cancer p
udy of nearly 30
still alive five ye
later study finds
astases that wo
te above 50 per
n cancers in
ions in the gene
and ovarian can
story of these c
gical removal of
ajor review of p
pausal women w
an and fallopian
g of tumors n
highly advance
sitive tissue that
machinery to va
he treatment of h
spinal cord, opt
ncer Milest
o treat patients w
is in a new clas
e cells known as
cer therapies to
tumor cells are
patients whose c
00 such patients
ears later, and n
s that use of po
uld have gone
rcent.
women at hi
es known as BR
ncers. Soon afte
cancers, may be
f their breasts
ublished studies
with BRCA muta
n tube cancers b
near sensitiv
ed radiation tech
t must be protec
ary both the sha
head and neck
ic nerve and sa
ones
9
with B-
ss of
s B
boost
cancer
s who
nearly
sitron
igh
RCA1
er,
e able
s
ations
by 79
e
hnique,
cted
ape
livary




1998
1998
1998
1998, 2006



Drug t
The FD
cancer,
approva
percent
BRCA2
is as eff
effects.
Treatm
Major s
Health t
increas
problem
Chem
treatm
A major
before s
conserv
shrink t
easier t
compar
cancers
6 First t
on car
The FD
the mon
breast c
adjuvan
trials sh
About 2
trastuzu
most ag
patients
therapy can
DA approves tam
to reduce the r
al is based on a
t in women with
2 genes. Later re
fective as tamox
ment guidelin
tudies linking ob
to publish clinic
ed risk for endo
ms.
otherapy bef
ment
r trial reports tha
surgery allows
ving surgery, ca
umors so they c
to recover from
red with mastec
s.
targeted anti-
re
DA approves the
noclonal antibod
cancer that over
nt therapy (after
how that it reduc
25 percent of bre
umab, there wer
ggressive, dead
s with stomach c

reduce breas
moxifen (Novald
risk of developin
a large trial show
a strong family
esearch shows
xifen at prevent
nes highligh
besity to an incr
al guidelines on
ometrial, breast,
fore surgery
at an approach
s more than two
alled lumpectom
can be removed
and results in fa
ctomy. Neoadjuv
-breast canc
e groundbreakin
dy to chemother
r-produces a pro
r surgery) for wo
ces the risk of re
east cancer pat
re no effective t
dly forms of the d
cancers that ha

st cancer ris
ex), a hormona
ng breast cance
wing that tamoxi
y history of breas
that a different d
ting invasive bre
t obesity-can
reased risk of co
n managing obe
prostate and co
y helps more
called neoadjuv
o-thirds of wome
y, instead of ful
d surgically. Bre
ar better cosme
vant therapy is l
cer drug, tras
g drug trastuzu
rapy dramatical
otein called HE
omen with early-
ecurrence by mo
tients have HER
treatments for th
disease. Recen
ve a similar ove
sk in women
al drug already u
er in women who
ifen reduced bre
st cancer or with
drug used to tre
east cancer, but
ncer link
ommon cancers
esity in adults. T
olon cancers, in
women ben
vant chemother
en with large bre
ll mastectomy. T
east-conserving
etic outcomes
ater shown to b
stuzumab (H
mab (Herceptin
ly increases su
R2. In 2006, the
-stage HER2-po
ore than 50 per
R2-positive disea
hese cancers, w
ntly, trastuzumab
er-production of
Major Can
at high risk
used to prevent
o are at high ris
east cancer risk
h mutations in t
eat osteoporosis
t with a lower ris
s prompt the Na
The guidelines p
n addition to oth
nefit from bre
rapy providing
east tumors to u
The goal of neo
surgery, also ca
without compro
benefit patients w
erceptin), ha
n) after research
rvival for wome
e drug is also ap
ositive breast ca
rcent, an unprec
ase, and prior to
which were cons
b was also FDA
f the HER2 prote
ncer Milest
recurrence of b
k for the diseas
k by more than 4
the BRCA1 and
s, raloxifene (Ev
sk of certain sid
ational Institutes
point specifically
her serious healt
east-conserv
g chemotherapy
undergo breast-
oadjuvant therap
alled lumpectom
omising survival
with rectal and
as major imp
h shows that add
n with advanced
pproved as part
ancer, after two
cedented result.
o the introductio
sidered some of
A-approved to tr
ein.
ones
10
breast
e. The
40
vista),
e
s of
y to the
th
ving
-
py is to
my, is

other
pact
ding
d
t of
major
.
on of
f the
eat




2000
2001
2001
19982003
2003
Study
The Iow
naturall
with inc
20,000
radon in
of the d
New ta
The FD
history
the maj
Philade
disease
a mana
Imatin
J ust we
shown t
to imati
breaker
growth
3 Doubl
Beginni
budget
over the
the clini
for canc
disease
Scient
Scientis
This ma
betwee
Results
researc
the dise
y links house
wa Radon Lung
y-occurring rad
creased risk of lu
lung cancer cas
nspections have
disease.
argeted ther
DA approves ima
based on data
ority of patients
elphia chromoso
e, and its effectiv
ageable, chronic
nib found hig
eeks after being
to be effective a
nib, available dr
r to block enzym
signal of a gene
ling of U.S. b
ing in 1998, Pre
increases for th
e next five years
ic, leading to im
cer research ha
e.
tists decode
sts announce th
arks the comple
n researchers in
s of the 13-year
ch to identify the
ease.

ehold radon e
Cancer Study d
ioactive gas tha
ung cancer. The
ses in the U.S. a
e become a rout
apy transfor
atinib (Gleevec)
a showing the d
s. Imatinib is the
ome, first disco
veness and eas
c disease.
ghly effective
approved to tre
against a rare ab
rug treatments h
mes that can se
e called c-Kit.
biomedical re
esident Bill Clinto
he National Insti
s. The new inve
mportant advanc
s declined in re
the human g
hat they have su
etion of the Hum
n the U.S. in an
effort are made
e genetic defects

exposure to
demonstrates th
at can emerge th
e Environmenta
are due to long-
tine part of hom
rms treatmen
after just three
drug halted the g
e first drug prove
overed in 1960.
sily-administered
e against rare
eat chronic mye
bdominal tumor
had little effect o
end faulty signal
esearch budg
on and Congres
tutes of Health,
estments accele
ces over the nex
al terms, potent
genome
uccessfully map
man Genome Pro
d six other coun
e freely available
s that fuel cance
lung cancer
hat ongoing exp
hrough baseme
al Protection Age
-term radon exp
meownership, pr
nt for rare leu
months of revie
growth of chron
en to counteract
It has since bec
d pill form enab
e gastrointes
logenous leuke
r called GIST (g
on GIST tumors
ls to trigger tum
get expands
ssional leaders
, doubling the ag
erate the pace o
xt decade. More
tially slowing the
ped the 3 billion
oject, an unprec
ntries, funded p
e to scientists a
er, and for new
Major Can
posure to reside
ents and crawl s
ency now estim
posure in the ho
romising to redu
ukemia
ew the fastest
ic myelogenous
t a molecular de
come the stand
bles most patien
stinal tumor
emia, the targete
gastrointestinal s
s. Imatinib work
mor cell growth. I
s cancer rese
enact a series o
gencys biomed
of cancer resear
e recently, howe
e pace of progr
n DNA letters in
cedented intern
rimarily by the U
round the world
ways of screen
ncer Milest
ntial radon a
spaces is asso
mates that more
ome. Since the s
uce the future bu
t approval in FD
s leukemia (CM
efect on the so-
ard of care for t
nts to live with C
ed drug imatinib
stromal tumor).
ks like a circuit
In GIST, it block
earch
of large, annual
dical research ef
rch in the lab an
ever, federal sup
ess against the
the human gen
ational collabor
U.S. governmen
d, paving the wa
ning for and trea
ones
11
ociated
than
study,
urden
DA
L) in
called
this
CML as
b is
Prior
ks the
l
fforts
nd in
pport
nome.
ration
nt.
ay for
ating




2003
2003, 2004
2004
2004, 2006
20042005
Obesi
An impo
for up to
along w
could b
As obes
the dise
4 First t
The FD
(Iressa)
on cell s
showing
treatme
time, st
These m
To date
therapie
also be
FDA a
Bevaciz
attack c
colorec
lung, ov
6 Two ta
The dru
spread
epiderm
coordin
patients
drugs a
for patie
5 Adjuv
In findin
surgery
commo
cancer.
impact
ty pinpointe
ortant prospecti
o 20 percent of
with several othe
e prevented ann
sity becomes m
ease will rise as
targeted drug
DA approves two
) and erlotinib (T
surfaces that is
g that erlotinib e
ent and that ge
udies show that
mutations are fo
e, the two drugs
es. But recent s
valuable first-lin
approves firs
zumab (Avastin)
cancer by blocki
tal cancer, in 20
varian and kidne
argeted drug
ugs cetuximab (
to other parts o
mal growth facto
ated analysis of
s with the norma
are used only for
ents who will no
vant therapy
ngs that quickly
y dramatically im
n form of the dis
These study re
on survival in lu

d as cause o
ve analysis invo
U.S. cancer de
er cancer types.
nually if Americ
more prevalent, r
well.
gs for lung c
o new targeted t
Tarceva). Both d
involved in driv
extends survival
efitinib delays th
t the drugs only
ound most often
are approved o
tudies indicate t
ne treatment op
st anti-angio
) is the first of a
ing the growth o
004, the drug ha
ey cancers, and
gs approved
Erbitux) and pa
of the body (met
or receptor (EGF
f multiple studie
al form of a gen
r patients who s
ot.
proven effec
change the sta
mproves surviva
sease. Previous
esults demonstra
ung cancer as it

of many canc
olving nearly 1 m
aths. Obesity is
The researche
ans maintained
researchers proj
cancer attack
treatments for a
drugs target the
ving lung cancer
l in patients with
he time before a
y work for patien
n in lung cancer
only for certain p
that for people w
ptions.
ogenic drug
new generation
of blood vessels
as since become
d for certain brai
for advance
nitumumab (Ve
astatic disease)
FR) protein, whi
es shows that ce
e known as KR
stand to benefit,
ctive in lung
ndard of care, c
l for patients wit
sly, chemothera
ate that adjuvan
does in breast
cer deaths
million American
s linked to a high
ers also estimate
a healthy weig
oject that deaths
k EGFR rec
advanced, non-s
e epidermal grow
r growth and sp
h advanced lung
a patients cance
nts with specific
patients who ne
patients whose
with the relevan
g, bevacizum
n of targeted dr
s that tumors ne
e an important t
in tumors, who h
ed colon canc
ectibix) are appr
). These drugs a
ich is involved in
etuximab and pa
RAS. This discov
, while eliminatin
cancer
clinical trials sho
th early-stage n
apy was conside
nt chemotherap
or colon cancer
Major Can
ns reports that o
her risk of death
e that 90,000 ca
ht.
s from liver canc
ceptor
small cell lung c
wth factor recep
read. Approval
g cancer a rar
er progresses. A
mutations in th
ever smoked.
cancer no longe
nt EGFR mutatio
mab
ugs, called anti-
eeds to grow. Fi
treatment for pa
have few other
cer
roved to treat co
attack tumors th
n cancer cell gro
anitumumab are
very helps phys
ng unnecessary
ow that giving ch
non-small cell lu
ered to be large
py could have an
r.
ncer Milest
obesity could ac
h from liver canc
ancer-related de
cer and other fo
cancer, gefitinib
ptor (EGFR), a p
is based on dat
re finding for an
Around the sam
e EGFR protein
er responds to o
ons, the drugs c
-angiogenics, th
rst approved to
atients with adva
effective option
olon cancer that
hat express the
owth. Later, a
e effective only
icians ensure th
y treatment and
hemotherapy af
ung cancer, the
ely ineffective fo
n equal or great
ones
12
ccount
cer,
eaths
rms of
protein
ta
y
me
n.
other
could
hat
treat
anced
ns.
t has
in
hat the
costs
fter
most
r lung
ter




2005
2005
2006
2009, 2010
U.S. la
The Na
The Ca
of the g
gaining
cancers
treatme
Resea
In the 1
focusing
survivo
the lung
survivo
The res
health o
First v
The FD
papillom
The vac
trial sho
those th
Cervari
women
and you
and gen
that the
0 Major
The pro
on whet
that PS
treatme
testing
evidenc
doctors
aunches effo
tional Cancer In
ncer Genome A
genomes of thre
a deeper unde
s, researchers h
ent.
arch sheds li
990s, research
g on survivors o
rs risk of long-t
gs was five tim
rs of other canc
sults are helping
of the millions of
vaccine appr
DA approves the
mavirus (HPV16
ccine, called Ga
owing that the v
hat cause genita
x, is approved i
aged 10 to 25.
ung adults aged
nital warts in ma
e vaccine may h
studies repo
oper role of PSA
ther routine test
A testing has m
ent of slow-grow
reduces the risk
ce, leading med
.

ort to map ca
nstitute and the
Atlas project. In
e common canc
rstanding of the
hope to identify
ght on long-
ers begin a maj
of childhood can
erm health prob
mes greater than
cers with high cu
g oncologists an
f cancer survivo
roved to prev
e first vaccine to
6 and HPV18) th
ardasil, is approv
accine was safe
al warts, for at le
n 2009 to preve
Gardasil is late
d 9 to 26, includi
ales. Studies ha
elp prevent thes
ort conflictin
A testing remain
ting reduces de
minimal, if any, e
wing cancers tha
k of prostate can
ical societies ur

ancer genom
National Huma
its initial phase,
cers lung, ova
e genetic pathwa
molecular targe
-term health
or study of the
ncer. In 2005, th
blems includin
n that of their he
ure rates, such a
nd primary care
ors alive today.
vent cervical
prevent infectio
hat are known to
ved for girls and
e and was 100 p
east four and a
ent infection aga
er approved to p
ing vaginal, vulv
ave also linked H
se cancers as w
ng results ab
ns uncertain afte
aths from prosta
effect on overall
at are unlikely to
ncer death in so
rge men to discu
mes
an Genome Res
, the project aim
arian, and gliobl
ays involved in
ets that can guid
problems of
long-term effect
he Childhood Ca
ng heart problem
ealthy siblings. S
as testicular can
providers monit
l cancer
on with two high
o cause about 7
d young women
percent effective
half years after
ainst the cancer
prevent additiona
var and anal ca
HPV infection to
well.
bout benefits
er large, random
ate cancer. Initi
survival and lea
o be life-threaten
ome men by 40
uss the risks an
Major Can
search Institute t
ms to develop a
astoma, a form
the developmen
de development
f cancer surv
ts of cancer and
ancer Survivors
ms, second canc
Similar results h
ncer.
tor and better m
h-risk strains of
70 percent of all
n aged 9 to 26, b
e against these
r vaccination. A
r-causing HPV s
al HPV-related
ncers in female
o head and neck
of PSA testi
mized trials prov
ial results from t
ads to the over-
ning. A third stu
percent. Given
nd benefits of sc
ncer Milest
team up to laun
comprehensive
of brain cancer
nt and growth o
t of effective new
vivors
d its treatment,
s Study reports t
cers and scarrin
have been foun
manage the long
the human
l cervical cance
based on a clini
types of HPV,
second vaccine
strains in young
diseases in chil
s, and anal can
k cancers, sugg
ing
vide conflicting r
two studies indi
-diagnosis and
udy finds that PS
the conflicting
creening with th
ones
13
nch
e atlas
r. By
f these
w
that
ng of
d for
g-term
rs.
ical
and
e,

ldren
ncer
gesting
esults
cate
SA
eir





2010
2010
2010
2011

CT sc
Results
reduces
former h
The Na
standar
the first
debate
howeve
First d
In a Pha
immune
advanc
Soon af
chemot
alone.
Addin
lung c
A head-
(specia
their dia
patients
likely to
potentia
Recor
The Na
of canc
nearly f
in the s
that has
cancer,
anning redu
s from a large cl
s the risk of lung
heavy smokers
tional Lung Scr
rd chest X-rays
t-ever lung canc
about the appro
er, continues.
drug shown t
ase III study, the
e system is fo
ed melanoma p
fter, a second tr
therapy drug co
ng palliative c
cancer patien
-to-head trial sh
lized treatment
agnosis with adv
s who had chem
o undergo aggre
al for palliative c
rd number of
tional Cancer In
er survivors in t
four-fold increas
ix years since 2
s led to improve
and cancer tre

ces lung can
inical trial show
g cancer death
.
eening Trial, fun
in this group of
cer screening ap
opriate use of L
to improve s
e targeted drug
und to improve
progresses desp
rial finds that tre
mmonly used in
care to stand
nts
hows that patien
to address the s
vanced lung can
motherapy alone
essive therapy a
care to no only i
f Americans
nstitute and the
the U.S. increas
se since 1971 (w
2001. The report
ed survival rates
atment, among

ncer deaths a
w that annual scr
by 20 percent, c
nded by the Nat
people at high
pproach that has
DCT screening
survival for p
ipilimumab (Ye
survival and de
pite other therap
eatment using a
n melanoma) ex
dard chemot
nts who received
symptoms of ca
ncer lived three
e. Patients who
at the end of life
mprove quality
surviving ca
Centers for Dis
sed to an all-time
when just 3 milli
t authors highlig
s, as well as the
survivors.
among heav
reening with low
compared to an
tional Cancer In
risk for develop
s been shown t
for lung cancer
patients with
ervoy) which b
elay disease pro
pies. The drug is
a combination of
xtends survival c
herapy impr
d standard chem
ancer, but not tr
e months longer
received the co
, such as resus
of life, but to ex
ancer nearl
sease Control an
e high of 11.7 m
ion survivors we
ght major progre
e need to addres
Major Can
vy smokers
w-dose spiral CT
nnual chest X-ra
nstitute, compar
ping lung cancer
to reduce lung c
r among the gen
advanced m
boosts a specific
ogression in pat
s approved for t
f ipilimumab and
compared to da
roves surviva
motherapy along
reat the disease
and had a high
ombination appr
citation. The res
xtend patients li
ly 12 million
nd Prevention r
million in 2007. T
ere alive) and a
ess in early dete
ss the long-term
ncer Milest
T (LDCT) scans
ays, in current a
red LDCT scann
r. This finding m
cancer mortality
neral population
melanoma
c component of
ients whose
this use in early
d dacarbazine (
acarbazine treat
al for advanc
g with palliative
e) immediately a
her quality of life
roach were also
sults demonstra
ives as well.
eport that the n
This represents
20 percent incr
ection and treat
m health effects
ones
14
s
nd
ning to
marks
. The
n,
f the
y 2011.
a
ment
ced
care
after
e than
less
ate the
umber
a
rease
tment
of